The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years<subtitle>The Swiss HIV Cohort Study</subtitle>
Open accessAbstract
BACKGROUND: Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 infection allows recovery of CD4 T lymphocytes. Few studies have explored the long-term T-lymphocyte responses to HAART. METHODS: Plasma HIV-1 RNA levels and CD4 and CD8 T-lymphocyte counts were longitudinally analyzed over 4 years in 2235 participants of the Swiss HIV Cohort, commencing HAART between 1996 and 1997. The CD4 T-lymphocyte count increase, the percentage of individuals with a CD4 T-lymphocyte count of 500/microL or greater and less than 200/microL, and the determinants of CD4 T-lymphocyte recovery were evaluated in individuals treated with continuous (CONT; n = 985) and discontinuous (DISCONT; n = 1250) HAART. RESULTS: At 4 years, 69.5% of subjects (CONT, 84.5%; DISCONT, 53.6%; P<.001) showed HIV-1 RNA levels below 400 copies/mL, while the median CD4 T-lymphocyte count increased from 190/microL to 423/microL (CONT, 486/microL; DISCONT, 343/microL; P<.001). Of the 2235 participants, 38.8% (CONT, 47.7%; DISCONT, 29.4%; P<.001) reached a CD4 T-lymphocyte count of 500/microL or greater, but in 15.6%, CD4 T-lymphocyte count remained below 200/microL (CONT, 5.9%; DISCONT, 25.9%; P<.001). Larger increases in CD4 T-lymphocyte count were associated with higher baseline HIV-1 RNA, a larger percentage of undetectable HIV-1 RNA levels, lower baseline CD8 T-lymphocyte count, and younger age. Individuals reaching a CD4 T-lymphocyte count of 500/microL or greater at 4 years were characterized by higher nadir and baseline CD4 T-lymphocyte counts and a more sustained reduction of HIV-1 RNA levels. CONCLUSIONS: At 4 years, only 39% of individuals treated with HAART reached a CD4 T-lymphocyte count of 500/microL or greater, and 16% with CD4 T-lymphocyte counts less than 200/microL remained susceptible to opportunistic infections. Treatment interruptions, a poor virologic response, and older age were the major factors negatively affecting the recovery of CD4 T lymphocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Changes in thymic function with age and during the treatment of HIV infection
Douek, D. C., McFarland, R. D., Keiser, P. H., Gage, E. A., Massey, J. M., Haynes, B. F., Polis, M. A., Haase, A. T., Feinberg, M. B., Sullivan#, J. L., et al. (1998) · Nature · doi:10.1038/25374 · Cited by 1,893
Egger, M., May, M., Chêne, G., Phillips, A. N., Ledergerber, B., Dabis, F., Costagliola, D., Monforte, A. D., de Wolf, F., Reiss, P., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09411-4 · Cited by 1,525
Changing patterns of mortality across Europe in patients infected with HIV-1
Mocroft, A., Vella, S., Benfield, T., Chiesi, A., Miller, V, Gargalianos, P., Monforte, A. D., Yust, I., Bruun, J., Phillips, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03201-2 · Cited by 1,270
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Greub, G., Ledergerber, B., Battegay, M., Grob, P., Perrin, L., Furrer, H., Burgisser, P., Erb, P., Boggian, K., Piffaretti, J.-C., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03232-3 · Cited by 894
Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy
Zhang, L., Ramratnam, B., Tenner-Racz, K., He, Y., Vesanen, M., Lewin, S., Talal, A., Racz, P., Perelson, A. S., Korber, B. T., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905273402101 · Cited by 807
Yeni, P. G., Hammer, S. M., Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., et al. (2002) · JAMA · doi:10.1001/jama.288.2.222 · Cited by 709
Egger, M., Hirschel, B., Francioli, P., Sudre, P., Wirz, M., Flepp, M., Rickenbach, M., Malinverni, R., Vernazza, P., & Battegay, M. (1997) · BMJ · doi:10.1136/bmj.315.7117.1194 · Cited by 615
Li, T., Tubiana, R., Katlama, C., Calvez, V, Mohand, H. A., & Autran, B. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10291-4 · Cited by 544
Ledergerber, B., Egger, M., Erard, V., Weber, R., Hirschel, B., Furrer, H., Battegay, M., Vernazza, P., Bernasconi, E., Opravil, M., et al. (1999) · JAMA · doi:10.1001/jama.282.23.2220 · Cited by 481
Infection with GB Virus C and Reduced Mortality among HIV-Infected Patients
Tillmann, H. L., Heiken, H., Knapik-Botor, A., Heringlake, S., Ockenga, J., Wilber, J. C., Goergen, B., Detmer, J., McMorrow, M., Stoll, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010398 · Cited by 399
Komanduri, K. V., Viswanathan, M. N., Wieder, E. D., Schmidt, D. K., Bredt, B. M., Jacobson, M. A., & McCune, J. M. (1998) · Nature Medicine · doi:10.1038/nm0898-953 · Cited by 389
Effect of Coinfection with GB Virus C on Survival among Patients with HIV Infection
Xiang, J., Wünschmann, S., Diekema, D. J., Klinzman, D., Patrick, K. D., George, S. L., & Stapleton, J. T. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003364 · Cited by 379
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Fellay, J., Ledergerber, B., Bernasconi, E., Furrer, H., Battegay, M., Hirschel, B., Vernazza, P., Francioli, P., Greub, G., Flepp, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06413-3 · Cited by 329
Furrer, H., Egger, M., Opravil, M., Bernasconi, E., Hirschel, B., Battegay, M., Telenti, A., Vernazza, P. L., Rickenbach, M., Flepp, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401701 · Cited by 249
Viard, J., Mocroft, A., Chiesi, A., Kirk, O., Røge, B., Panos, G., Vetter, N., Bruun, J. N., Johnson, M., Lundgren, J. D., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/319678 · Cited by 220
Yamashita, T. E., Phair, J. P., Muñoz, A., Margolick, J. B., Detels, R., O'Brien, S. J., Mellors, J. W., Wolinsky, S. M., & Jacobson, L. P. (2001) · AIDS · doi:10.1097/00002030-200104130-00009 · Cited by 178
Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
Staszewski, S., Miller, V., Sabin, C. A., Schlecht, C., Gute, P., Stamm, S., Leder, T., Berger, A., Weidemann, E., Hill, A., et al. (1999) · AIDS · doi:10.1097/00002030-199905280-00011 · Cited by 138
Angel, J. B., Kumar, A., Parato, K., Filion, L. G., Díaz‐Mitoma, F., Daftarian, P. M., Pham, B., Sun, E., Leonard, J. M., & Cameron, D. W. (1998) · The Journal of Infectious Diseases · doi:10.1086/515244 · Cited by 124
Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy
Kaufmann, G. R., Bloch, M., Zaunders, J., Smith, D. E., & Cooper, D. A. (2000) · AIDS · doi:10.1097/00002030-200005260-00007 · Cited by 101
Self-citationKaufmann, G. R., Zaunders, J., Cunningham, P., Kelleher, A. D., Grey, P., Smith, D. E., Carr, A. J., & Cooper, D. A. (2000) · AIDS · doi:10.1097/00002030-200012010-00003 · Cited by 97
Self-citationLecossier, D., Bouchonnet, F., Schneider, P., Clavel, F., & Hance, A. J. (2001) · The Journal of Infectious Diseases · doi:10.1086/319285 · Cited by 71
Cited by
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa
Lawn, S. D., Harries, A. D., Anglaret, X., Myer, L., & Wood, R. (2008) · AIDS · doi:10.1097/qad.0b013e32830007cd · Cited by 639
Jiang, W., Lederman, M. M., Hunt, P., Sieg, S. F., Haley, K., Rodriguez, B., Landay, A., Martin, J., Sinclair, E., Asher, A. I., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/597476 · Cited by 591
Bhaskaran, K. (2008) · JAMA · doi:10.1001/jama.300.1.51 · Cited by 496
Antiretroviral therapy and management of HIV infection
Volberding, P. A., & Deeks, S. G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60676-9 · Cited by 449
Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS
Biggar, R. J., Jaffe, E. S., Goedert, J. J., Chaturvedi, A., Pfeiffer, R., Engels, E. A., & Study, F. T. H. C. M. (2006) · Blood · doi:10.1182/blood-2006-05-024109 · Cited by 436
Metadata
- Authors
- Kaufmann, G. R.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2003-10-13
- Volume
- 163
- Issue
- 18
- Pages
- 2187
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2144361427
- Cited by
- 409
- References
- 23
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.